We canât show the full text here under this license. Use the link below to read it at the source.
Research advances in the diagnosis and treatment of MASLD/MASH
New developments in diagnosing and treating fatty liver disease and its inflammatory form
AI simplified
Abstract
Recent advancements in diagnosing and treating Metabolic Dysfunction-Associated Steatotic Liver Disease () and its progression to Metabolic Dysfunction-Associated Steatohepatitis () have emerged.
- Non-invasive diagnostic tools like high-resolution CT, MRI, FIB-4 index, and FAST score improve early detection and accuracy.
- Pharmaceutical treatments include THR-β agonists, FXR agonists, PPAR agonists, GLP-1 receptor agonists, and SGLT2 inhibitors, along with lifestyle changes.
- Surgical options such as gastric bypass and liver transplantation are effective, especially for obese and advanced MASH patients.
- There are ongoing challenges in standardizing treatment protocols and validating long-term efficacy.
- Future research may focus on personalized treatment approaches and multidisciplinary collaboration to enhance patient care.
AI simplified